✦ LIBER ✦

Adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer (SCLC)

Book ID: 123472922
Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 95 KB
Volume: 2
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(86)80660-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival, adverse reactions and quality

Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer

✍ Bleehen, N.M.; Fayers, P.M.; Girling, D.J.; Stephens, R.J. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 555 KB

793 Five day oral etoposide treatment fo

793 Five day oral etoposide treatment for advanced small cell lung cancer (SCLC): Quality of life (QOL) assessment in a randomised comparison with intravenous chemotherapy

✍ Harper, P.G.; James, L.E.; Spiro, S.G.; Rudd, R.M.; Ruiz de Elvira, M.-C.; Gower 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 292 KB

Phase II Study of Efficacy and Safety of

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer

✍ Herbst, R. S.; O'Neill, V. J.; Fehrenbacher, L.; Belani, C. P.; Bonomi, P. D.; H 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 144 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB